DEC-C and Thioguanine for R/R AML - Trial NCT06351306
Access comprehensive clinical trial information for NCT06351306 through Pure Global AI's free database. This Phase 2 trial is sponsored by Joseph Jurcic and is currently Recruiting. The study focuses on Acute Myeloid Leukemia. Target enrollment is 48 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Joseph Jurcic
Columbia University
Timeline & Enrollment
Phase 2
Jan 30, 2024
Dec 01, 2027
Primary Outcome
Composite Complete Remission (CRc) Rate
Summary
The purpose of this study is to find out if oral decitabine-cedazuridine (Inqovi®) is
 effective, safe, and able to be tolerated without severe side effects when given with
 thioguanine (Tabloid®) in patients with acute myeloid leukemia (AML) whose disease has
 returned or did not respond to treatment (relapsed or refractory).
 
 This is a phase II trial with a safety lead-in. The goal of the lead-in portion of the
 study is to make sure participants are getting the highest dose of medications that are safe.
 If too many serious side effects are seen with the dose previously studied, some additional
 patients may be treated with a lower dose to make sure that this dose is safe.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06351306
Non-Device Trial